Navigation Links
Ann Arbor SPARK Receives $3.75M from Michigan's Company Formation & Growth Fund
Date:11/29/2007

Five Companies Receive Initial Funding to Retain Pfizer Assets, Talent

ANN ARBOR, Mich., Nov. 29 /PRNewswire/ -- Ann Arbor SPARK has been awarded $3.75 million by the state of Michigan through the 21st Century Jobs Fund. The Company Formation and Growth Fund, a state of Michigan loan fund with a low interest rate, is intended to encourage the retention of Pfizer assets and talent in the region. Job creation is vital for consideration for approval of funding through the Company Formation and Growth Fund.

"The Company Formation and Growth Fund provides the essential capital for jobs creation as well as support for start-up companies that can retain displaced Pfizer talent in our region," explained Michael A. Finney, Ann Arbor SPARK CEO. "Providing an economic catalyst for entrepreneurial growth is vital to our region's success; the Company Formation and Growth Fund's focus on creating new jobs for talented biotech professionals is an exciting opportunity."

Ann Arbor SPARK has distributed $1.5 million of the funds it received to five life science companies in the region:

-- Phrixus Pharmaceuticals, a heart repair pharmaceutical company based in

Ann Arbor that is focused on therapeutic drug discovery for heart

failure, was awarded $350,000.

-- Jackson-based TransPharm Preclinical Solutions, specializing in animal

infection studies and contract research studies to test new antibiotic

drugs, was awarded $400,000.

-- SensiGen LLC, based in Ann Arbor, was awarded $300,000, to support its

gene-based molecular diagnostics work.

-- Ann Arbor-based Lycera, Inc., awarded $400,000, develops small molecule

drugs for the treatment of psoriasis, rheumatoid arthritis, lupus and

cancer.

-- Integrated Nonclinical Development Solutions, Inc., based in Ann Arbor,

awarded $50,000, provide toxicology providing consulting and informatic

servic
'/>"/>

SOURCE Ann Arbor SPARK
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. New Competitive Intelligence Speakers Spark Interest in Pharmaceutical Conference on October 1-2 in NJ
2. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
3. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
4. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
5. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
6. IsoTis Receives FDA Clearance for Accell Family of Products
7. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
8. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
9. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
10. XTL Receives Staff Letter From NASDAQ
11. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 2013 Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" ... host a teleconference to discuss its First Quarter 2013 ... teleconference information is provided below: Date: Thursday, ... (EDT) Dial-in: (800) 875-3456 (U.S.); (800) 648-0973 ... VS22823 For those unable to participate in ...
(Date:5/23/2013)... 23, 2013 African Ancestry ... for people of African descent, today announced new ... For people of all races, myDNAmix determines various ... distinct populations: Indigenous Americas (Native American), East Asia, ... , Originally launched in late 2011, ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Just released this ... executive coach and author Barbara Roche: “Commit to Confidence: ... , Filled with helpful tips and quotes from the fields ... leaders, and tangible exercises that readers can do on their ... to achieve their personal and professional goals. , ...
(Date:5/22/2013)... The Conference Forum announced the ... Clinical Trials conference taking place on September 19-20 at ... , Disruptive thinkers from Novartis, Pfizer, Eli Lilly, Shire, ... to reduce expensive infrastructure, engage patients and generate credible ... big, or novel, or it must change the very ...
Breaking Biology Technology:Pressure BioSciences, Inc. to Discuss First Quarter 2013 Financial Results and Provide Business Update 2AfricanAncestry.com Rolls Out Improved MyDNAMix Admixture Test for People of all Races; Enhancements Increase Accuracy in Estimation of Ancestral Makeup 2AfricanAncestry.com Rolls Out Improved MyDNAMix Admixture Test for People of all Races; Enhancements Increase Accuracy in Estimation of Ancestral Makeup 3Disruptive Innovation Hits Clinical Trials, Dedicated Event Launches 2
... DX Frequently Changes Treatment ... Recommendations in Clinical Practice -, REDWOOD CITY, Calif., Nov. ... the publication of results from a study,indicating that Oncotype DX(R) ... The study, published in the,October issue of the American Journal ...
... China, Nov. 10 /Xinhua-PRNewswire/ -- 3SBio Inc. (Nasdaq:,SSRX), ... and marketing biopharmaceutical products primarily in China,today announced ... Food and Drug,Administration (SFDA) for approval of NuLeusin ... carcinoma. If approved, NuLeusin is expected to,be the ...
... New Data Presented at the Meeting Report the ... Benefit From Tight Glycemic Control in,Diabetics, MONTVALE, ... SYI ) today announced at the Annual Scientific,Sessions ... Orleans, that a,new clinical test to determine haptoglobin ...
Cached Biology Technology:Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated 2Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated 3Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated 43SBio Inc. Files for SFDA Approval of NuLeusin 23SBio Inc. Files for SFDA Approval of NuLeusin 33SBio Inc. Files for SFDA Approval of NuLeusin 4Synvista Therapeutics Announces Availability of Haptoglobin Genotyping Technology at The Annual Scientific Sessions of the American Heart Association 2Synvista Therapeutics Announces Availability of Haptoglobin Genotyping Technology at The Annual Scientific Sessions of the American Heart Association 3Synvista Therapeutics Announces Availability of Haptoglobin Genotyping Technology at The Annual Scientific Sessions of the American Heart Association 4Synvista Therapeutics Announces Availability of Haptoglobin Genotyping Technology at The Annual Scientific Sessions of the American Heart Association 5
(Date:5/21/2013)... COLUMBIA, Mo. Cancers of all types become most ... body. Once cancer has reached this stage, it becomes ... numerous tumors that can develop. Now, researchers at the ... radioactive nanoparticles that target lymphoma tumor cells wherever they ... professor of oncology in the MU College of Veterinary ...
(Date:5/21/2013)... and health stores, phosphatidylserine is a natural food ... to improve cognition and slow memory loss, it,s ... impairment. Now a team headed by Prof. Gil ... University,s Department of Human Molecular Genetics ... functioning of genes involved in degenerative brain disorders, ...
(Date:5/21/2013)... in shape is an uphill battle? Try staying fit ... weightlessness withers muscle and bone. , That,s the challenge ... with a new three-year, $1.2 million grant from NASA. ... during multiyear exploratory missions. , "You could give astronauts ... can,t get them to stick to it, it isn,t ...
Breaking Biology News(10 mins):MU researchers develop radioactive nanoparticles that target cancer cells 2Common food supplement fights degenerative brain disorders 2Fueling fitness on the final frontier 2
... N.Y. A cell,s genome maintains its integrity by ... of DNA called heterochromatin. In the comparatively simple organism ... (RNAi) plays an essential role in assembling heterochromatin, which ... state. Central to this process is a large protein ...
... Researchers at Harvard Medical School and Children,s Hospital ... infection as it spread among cystic fibrosis patients by ... contained. A significant achievement in genetic pathology, the work ... see evolution as it happensand sheds new light on ...
... higher levels of high sensitivity C-Reactive protein (hsCRP) and shorter ... patients, in research presented at the American Heart Association,s Scientific ... intake from food, heart failure patients in the study who ... to have higher levels of hsCRP, a marker for inflammation ...
Cached Biology News:CSHL team solves a protein complex's molecular structure to explain its role in gene silencing 2Bacterial genes tell the tale of an outbreak's evolution 2Bacterial genes tell the tale of an outbreak's evolution 3Bacterial genes tell the tale of an outbreak's evolution 4Low vitamin C levels may raise heart failure patients' risk 2
... allows detection of SYBR Green I or ... range of fluorophores in the second channel ... for a multitude of applications such ... thermal cycler offers precision thermal control and ...
Fingerprinting II database sharing tools is an optional module for the Fingerprinting II Basic software package that enables peer-to-peer data exchange over the internet and provides external databas...
Fingerprinting II dimensioning techniques is an optional module that adds principal component analysis, multidimensional scaling, discriminant analysis and MANOVA, and self-organizing maps to the Fin...
... II Informatix dimensioning ... optional module that ... analysis, multidimensional scaling, ... MANOVA, and self-organizing ...
Biology Products: